• Citer

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial

par Aftimos, Philippe ;Polastro, Laura;Ameye, Lieveke;Jungels, C.;Vakili, Jalal ;Paesmans, Marianne ;Van Den Eerenbeemt, Joanne;Buttice, A;Gombos, Andrea ;de Valeriola, Dominique ;Gil, Thierry ;Piccart-Gebhart, Martine ;Awada, Ahmad
Référence European journal of cancer, 60, page (117-124)
Publication Publié, 2016-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial
Auteur:	Aftimos, Philippe; Polastro, Laura; Ameye, Lieveke; Jungels, C.; Vakili, Jalal; Paesmans, Marianne; Van Den Eerenbeemt, Joanne; Buttice, A; Gombos, Andrea; de Valeriola, Dominique; Gil, Thierry; Piccart-Gebhart, Martine; Awada, Ahmad
Informations sur la publication:	European journal of cancer, 60, page (117-124)
Statut de publication:	Publié, 2016-06
Sujet CREF:	Cancérologie
Mots-clés:	Breast cancer
	Chemotherapy
	Cross-resistance
	Eribulin
	Metastatic
	Safety
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2016.03.010
	info:pii/S0959804916001866
	info:scp/84964342351